PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
PolarityTE, a biotech firm focusing on regenerative tissue products, hosted a conference call on August 11, 2022, to discuss its Q2 financial results and business updates. As of June 30, 2022, the company reported a cash reserve of $20.5 million and working capital of $19.4 million. Key highlights included the FDA's January approval for human clinical trials for its SkinTE product and the RMAT designation granted in May, which accelerates the development process for diabetic foot ulcer indications. The company does not expect revenue from operations for the foreseeable future due to previous business ceases and ongoing restructuring.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for SkinTE, enabling expedited dialogue for Biologics License Application (BLA).
- Plans for a second randomized controlled trial to further support SkinTE's approval for diabetic foot ulcers, targeting completion by end of 2023.
- Significant reduction in operating costs by $5.2 million or 25% in the six-month period compared to the previous year.
- No revenue generated in the first half of 2022 due to cessation of SkinTE sales and services from the IBEX subsidiary.
- Operating loss decreased only slightly by $1.2 million (7%) over the same period, indicating ongoing financial strain.
- Net loss decreased by $16.8 million (81%) but reflects prior high losses, highlighting ongoing financial challenges.
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET
SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022.
- In January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND) for SkinTE. In May 2022, the FDA granted PolarityTE's request for SkinTE to be designated as a Regenerative Medicine Advanced Therapy (RMAT). As a result of the RMAT designation the Company was able to engage in an expedited dialogue with the FDA on the tasks that are likely to be necessary to support a Biologics License Application (BLA) for SkinTE. Based on that dialogue the Company plans to run a second multi-center, randomized controlled trial under its current IND to support approval of a broad diabetic foot ulcers (DFUs) indication for SkinTE in a BLA, and the Company plans to follow-up with the FDA regarding the design and implementation of the second clinical trial. The Company believes this strategy will be the fastest and least costly approach to achieving its first BLA submission for SkinTE, with DFUs representing the largest market opportunity within the category of chronic cutaneous ulcers. The Company plans to further engage with the FDA to fully define its development plan for other wound indications.
- In May 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND. The RCT will enroll up to 100 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone. The primary endpoint is the incidence of DFUs closed at 24 weeks. Secondary endpoints include percent area reduction (PAR) at 4, 8, 12, 16 and 24 weeks; improved quality of life, including social isolation, depression, odor, improved function, ambulation, and return to activities based on changes in wound quality of life; and new onset infection of the DFU requiring treatment with topical and/or systemic antibiotics. The Company estimates that it may be able to complete enrollment of 100 subjects by the end of calendar year 2023.
- At the end of April 2022, the Company sold its preclinical research services business operated under its subsidiary, IBEX Preclinical Research, Inc. ("IBEX"), and related real estate assets, and the Company received a promissory note in the principal amount of
$0.4 million for the IBEX business and net cash proceeds of$2.3 million from the sale of the real property associated with that business. - The Company had cash and cash equivalents of
$20.5 million and working capital of$19.4 million at June 30, 2022.
Richard Hague, Chief Executive Officer, commented, "The RMAT designation we achieved has already benefited us by expediting direct communication with the FDA, which has provided important guidance on the milestones we need to achieve to efficiently advance our development program for SkinTE in the DFU indication, and what additional work we may need to do to for SkinTE to be approved for other indications. This will allow us to prioritize our efforts to advance SkinTE and effectively manage our capital and resources accordingly."
There have been significant changes in the Company's operations affecting its results of operations for the six-month period ended June 30, 2022, compared to six-month period ended June 30, 2021.
On July 23, 2021, the Company submitted an IND for SkinTE to the FDA as the first step in the regulatory process for obtaining licensure for SkinTE under Section 351 of the Public Health Service Act. The FDA subsequently issued clinical hold correspondence identifying certain issues that needed to be addressed before the IND could be approved. The Company provided responses to the FDA, and on January 14, 2022, the FDA sent correspondence informing the Company that the clinical hold had been removed. Acceptance of the IND by the FDA enables the Company to commence the first of two expected pivotal studies needed to support a BLA for SkinTE. The Company ceased selling SkinTE at the end of May 2021, when the period of enforcement discretion previously announced by the FDA with respect to its IND and premarket approval requirements for regenerative medicine therapies, such as SkinTE, came to an end, and the Company does not expect to be able to commercialize SkinTE until a BLA is approved, which the Company believes will take at least three to four years. Consequently, the Company recognized products net revenues in the six months of 2021, and did not have any such revenues in the first six months of 2022.
The Company's subsidiary, Arches Research, Inc. ("Arches") began offering COVID-19 testing services in May 2020 under 30-day renewable testing agreements with multiple nursing home and pharmacy facilities in the state of New York controlled by a single company, which substantially added to the Company's services net revenues in the first three months of 2021. When the New York nursing homes and pharmacies adopted on-site employee testing at the end of March 2021, the Company's COVID-19 testing revenues declined substantially, and in August 2021, the Company decided to cease COVID-19 testing. Arches focused its research and development resources on supporting our IND and clinical trial efforts for the remainder of 2021 and continued in that role in the first quarter of 2022. However, going forward the Company does not expect it will have the same need for research and development staff associated with product development and, as a result, the Company reduced research and development staff in April 2022, and began to eliminate or sell certain items of equipment that had been leased or purchased for its research and development activity.
While the Company was exploring the opportunities for selling IBEX and the real property used in the IBEX business, IBEX assumed a more passive approach to marketing its services, which resulted in a decline in IBEX services revenues in the first six months of 2022 compared to the first six months of 2021. With the sale of IBEX and related real property completed at the end of April 2022, the Company's services net revenues were nominal in the first six months of 2022 and the Company does not expect any services net revenues in the last six months of 2022.
As a result of the foregoing developments, the Company made a number of changes to its operations that impacted its results of operations. These included reductions in work force and reducing the services and infrastructure needed to support a larger work force and commercial sales effort.
Comparison of the six months and three months ended June 30, 2022, to the six months and three months ended June 30, 2021
Net Revenues and Gross Profit. The Company ceased commercial sales of SkinTE in the second calendar quarter of 2021 and sold the IBEX services business at the end of April 2022, so the Company was not engaged in any revenue generating business activity at June 30, 2022, and does not expect to generate operating revenues from any business activity for the foreseeable future. The decreases in revenues, cost of revenues, and gross (loss) profit for the six-month and three-month periods ended June 30, 2022, compared to the same periods in 2021 are consistent with the Company's cessation of revenue-generating business activity.
Operating Costs and Expenses. Operating costs and expenses decreased
Research and development expenses decreased
The amount of general and administrative expenses decreased
In the first six months of 2021, the Company incurred sales and marketing costs related to its commercial sales effort that did not recur in the first six months of 2022. In connection with terminating commercial sales of SkinTE, the Company realized as a restructuring charge a loss on impairment of property and equipment in the amount of
Operating Loss and Net Loss. Operating loss decreased
Net loss decreased
The table below provides a reconciliation of adjusted net loss, which is a non-GAAP measure that shows net loss before fair value adjustments relating to the Company's common stock warrant liability and warrant inducement loss, to GAAP net loss. The Company believes adjusted net loss is useful to investors because it eliminates the effect of non-operating items that can significantly fluctuate from period to period due to fair value remeasurements. For purposes of calculating non-GAAP per share metrics, the same denominator is used as that which was used in calculating net loss per share under GAAP. Other companies may calculate adjusted net loss differently than the Company does. Adjusted net loss has limitations as an analytical tool and you should not consider adjusted net loss in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP.
Adjusted Net Loss Attributable to Common Stockholders | ||||||||||||||||
(in thousands - unaudited non-GAAP measure) | ||||||||||||||||
For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
GAAP Net Loss | $ | (68) | $ | (3,188) | $ | (3,839) | $ | (20,598) | ||||||||
Change in fair value of common stock warrant liability | (6,630) | (1,807) | (11,735) | 2,220 | ||||||||||||
Inducement loss on sale of liability classified warrants | – | – | – | 5,197 | ||||||||||||
Non-GAAP adjusted net loss attributable to common | $ | (6,698) | $ | (4,995) | $ | (15,574) | $ | (13,181) | ||||||||
GAAP net loss per share attributable to common stockholders | ||||||||||||||||
Basic* | $ | (0.01) | $ | (0.99) | $ | (0.85) | $ | (6.57) | ||||||||
Diluted* | $ | (0.49) | $ | (1.01) | $ | (1.37) | $ | (6.57) | ||||||||
Non-GAAP adjusted net loss per share attributable to | ||||||||||||||||
Basic and diluted* | $ | (1.30) | $ | (1.55) | $ | (3.45) | $ | (4.20) | ||||||||
* Giving retroactive effect to the 1-for-25 reverse stock split effectuated on May 16, 2022 |
The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accessed by using the link below.
Earnings Call Webcast - CLICK HERE
A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE's website at https://www.polarityte.com/news-media/events, or by clicking on the link above.
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA). SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic, future clinical studies, and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.
CONTACTS
Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
385-831-5284
Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com
Ignacio.guerrero-ros@russopartnersllc.com
POLARITYTE, INC. AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited, in thousands, except share and per share amounts) | ||||||||
June 30, 2022 | December 31, 2021 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 20,518 | $ | 19,375 | ||||
Accounts receivable, net | – | 978 | ||||||
Assets held for sale | 387 | 441 | ||||||
Prepaid expenses and other current assets | 1,992 | 1,595 | ||||||
Total current assets | 22,897 | 22,389 | ||||||
Property and equipment, net | 3,670 | 6,923 | ||||||
Operating lease right-of-use assets | 554 | 1,146 | ||||||
Other assets | 910 | 720 | ||||||
TOTAL ASSETS | $ | 28,031 | $ | 31,178 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued expenses | $ | 1,944 | $ | 3,115 | ||||
Other current liabilities | 1,568 | 1,520 | ||||||
Deferred revenue | – | 74 | ||||||
Total current liabilities | 3,512 | 4,709 | ||||||
Common stock warrant liability | 4,222 | 6,844 | ||||||
Operating lease liabilities | 63 | 43 | ||||||
Other long-term liabilities | 188 | 338 | ||||||
Total liabilities | 7,985 | 11,934 | ||||||
Commitments and Contingencies (Note 16) | ||||||||
STOCKHOLDERS' EQUITY | ||||||||
Preferred stock – 25,000,000 shares authorized, 0 shares issued | – | – | ||||||
Common stock - $.001 par value; 250,000,000 shares authorized; | 5 | 3 | ||||||
Additional paid-in capital | 532,278 | 527,639 | ||||||
Accumulated deficit | (512,237) | (508,398) | ||||||
Total stockholders' equity | 20,046 | 19,244 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 28,031 | $ | 31,178 | ||||
* Giving retroactive effect to the 1-for-25 reverse stock split effectuated on May 16, 2022 |
POLARITYTE, INC. AND SUBSIDIARIES | ||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||||
(Unaudited, in thousands, except share and per share amounts) | ||||||||||||||||||
For the Three Months Ended | For the Six Months Ended | |||||||||||||||||
June 30, | June 30, | |||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||
Net revenues | ||||||||||||||||||
Products | $ | – | $ | 1,195 | $ | – | $ | 2,924 | ||||||||||
Services | 73 | 1,342 | 814 | 4,322 | ||||||||||||||
Total net revenues | 73 | 2,537 | 814 | 7,246 | ||||||||||||||
Cost of revenues | ||||||||||||||||||
Products | – | 207 | – | 448 | ||||||||||||||
Services | 125 | 717 | 616 | 2,641 | ||||||||||||||
Total costs of revenues | 125 | 924 | 616 | 3,089 | ||||||||||||||
Gross (loss) profit | (52) | 1,613 | 198 | 4,157 | ||||||||||||||
Operating costs and expenses | ||||||||||||||||||
Research and development | 3,078 | 4,190 | 5,938 | 6,621 | ||||||||||||||
General and administrative | 3,562 | 4,941 | 9,771 | 11,312 | ||||||||||||||
Sales and marketing | – | 1,099 | – | 2,625 | ||||||||||||||
Restructuring and other charges | 38 | 11 | 38 | 436 | ||||||||||||||
Impairment of assets held for sale | – | – | 54 | – | ||||||||||||||
Total operating costs and expenses | 6,678 | 10,241 | 15,801 | 20,994 | ||||||||||||||
Operating loss | (6,730) | (8,628) | (15,603) | (16,837) | ||||||||||||||
Other income (expense), net | ||||||||||||||||||
Gain on extinguishment of debt | – | 3,612 | – | 3,612 | ||||||||||||||
Change in fair value of common stock | 6,630 | 1,807 | 11,735 | (2,220) | ||||||||||||||
Inducement loss on sale of liability | – | – | – | (5,197) | ||||||||||||||
Interest expense, net | (14) | (39) | (29) | (77) | ||||||||||||||
Other income, net | 46 | 60 | 58 | 121 | ||||||||||||||
Net loss and comprehensive loss | $ | (68) | $ | (3,188) | $ | (3,839) | $ | (20,598) | ||||||||||
Net loss per share attributable to | ||||||||||||||||||
Basic* | $ | (0.01) | $ | (0.99) | $ | (0.85) | $ | (6.57) | ||||||||||
Diluted* | $ | (0.49) | $ | (1.01) | $ | (1.37) | $ | (6.57) | ||||||||||
Weighted average shares outstanding | ||||||||||||||||||
Basic* | 5,148,106 | 3,224,117 | 4,512,692 | 3,135,715 | ||||||||||||||
Diluted* | 5,418,552 | 3,246,490 | 4,803,671 | 3,135,715 | ||||||||||||||
* Giving retroactive effect to the 1-for-25 reverse stock split effectuated on May 16, 2022 |
POLARITYTE, INC. AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(Unaudited, in thousands) | ||||||||
For the Six Months Ended June 30, | ||||||||
2022 | 2021 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (3,839) | $ | (20,598) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation expense | 1,292 | 3,124 | ||||||
Depreciation and amortization | 858 | 1,437 | ||||||
Impairment of assets held for sale | 54 | – | ||||||
Amortization of intangible assets | – | 95 | ||||||
Bad debt expense | – | 134 | ||||||
Inventory write-off | – | 697 | ||||||
Gain on extinguishment of debt – PPP loan | – | (3,612) | ||||||
Change in fair value of common stock warrant liability | (11,735) | 2,220 | ||||||
Inducement loss on sale of liability classified warrants | – | 5,197 | ||||||
Loss on restructuring and other charges | – | 269 | ||||||
(Gain) loss on sale of property and equipment | (36) | 7 | ||||||
Gain on sale of subsidiary and property | (32) | – | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 396 | 1,643 | ||||||
Inventory | – | 110 | ||||||
Prepaid expenses and other current assets | (187) | (1,294) | ||||||
Operating lease right-of-use assets | 592 | 666 | ||||||
Other assets/liabilities, net | – | 245 | ||||||
Accounts payable and accrued expenses | (1,015) | (221) | ||||||
Other current liabilities | – | (14) | ||||||
Deferred revenue | (51) | (82) | ||||||
Operating lease liabilities | (564) | (728) | ||||||
Net cash used in operating activities | (14,267) | (10,705) | ||||||
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (31) | (18) | ||||||
Proceeds from sale of property and equipment | 165 | 10 | ||||||
Proceeds from sale of subsidiary and property, net of selling expenses and cash sold | 2,327 | – | ||||||
Net cash provided by/(used in) investing activities | 2,461 | (8) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds from insurance financing arrangements | 1,027 | 1,028 | ||||||
Principal payments on term note payable and financing arrangements | (353) | (359) | ||||||
Principal payments on financing leases | (186) | (272) | ||||||
Net proceeds from the sale of common stock, warrants and pre-funded warrants | 7,823 | 9,884 | ||||||
Proceeds from the sale of warrants | – | 1,002 | ||||||
Proceeds from warrants exercised | – | 6,671 | ||||||
Proceeds from pre-funded warrants exercised | 1 | 8 | ||||||
Net proceeds from the sale of preferred stock and warrants | 4,814 | – | ||||||
Cash paid for tax withholdings related to net share settlement | (179) | (188) | ||||||
Proceeds from stock options exercised | – | 3 | ||||||
Proceeds from ESPP purchase | 2 | 28 | ||||||
Net cash provided by financing activities | 12,949 | 17,805 | ||||||
Net increase in cash and cash equivalents | 1,143 | 7,092 | ||||||
Cash and cash equivalents - beginning of period | 19,375 | 25,522 | ||||||
Cash and cash equivalents - end of period | $ | 20,518 | $ | 32,614 | ||||
Supplemental cash flow information: | ||||||||
Cash paid for interest | $ | 39 | $ | 66 | ||||
Supplemental schedule of non-cash investing and financing activities: | ||||||||
Fair value of placement agent warrants issued in connection with offerings | $ | 417 | $ | 838 | ||||
Reclassification of warrant liability to stockholders' equity upon exercise of warrant | $ | – | $ | 8,964 | ||||
Conversion of Series A and Series B preferred stock into common stock | $ | 16 | $ | – | ||||
Allocation of financing to warrant liability | $ | 9,113 | $ | 8,629 | ||||
Deferred and accrued offering costs | $ | 98 | $ | 400 | ||||
Sale of assets held for sale in exchange for a note receivable | $ | 400 | $ | – | ||||
Reclassification of lease deposit to short term | $ | 210 | $ | – | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-reports-second-quarter-2022-financial-results-and-provides-business-update-301604447.html
SOURCE PolarityTE, Inc.
FAQ
What were PolarityTE's financial results for Q2 2022?
What is the significance of the RMAT designation for PolarityTE?
When does PolarityTE expect to complete its clinical trial for SkinTE?
What was the impact of the FDA's clinical hold on PolarityTE's operations?
